News >

Expert Highlights Genetic Testing, Immunotherapy in Endometrial Cancer

Angelica Welch
Published: Thursday, Jan 11, 2018

Martee L. Hensley, MD

Martee L. Hensley, MD
Mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) testing may improve classifications of endometrial cancer and lead to personalized treatment options, according to Martee L. Hensley, MD.

, Hensley, a medical oncologist at Memorial Sloan Kettering Cancer Center (MSK), discussed the role of MSI-H and dMMR testing in the management of endometrial cancer.

OncLive: What is the role of MSI-H testing in endometrial cancer?

Hensley: Previously, we classified endometrial cancers as either type 1 endometrial tumors or type 2 serous cancers—a distinction that we made mostly by histology. I argue that we can use dMMR testing and MSI-high testing to better classify our cancers, and that has treatment implications. One of the reasons that I argue that we should do that type of testing is to help us increase the number of patients we identify as potential carriers of germline mutations and mismatch-repair enzymes. [This is] a group of patients who we call [having] Lynch syndrome.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication